Azura Ophthalmics

Press Release Azura Ophthalmics Corporate Update: AZR-MD-001 NDA Submission Expected in 2H 2026 December 10, 2025 -Following a Positive U.S. Food and Drug Administration (FDA) pre-New Drug Application (NDA) Meeting for AZR-MD-001, Company Plans NDA Submis

Press Release Azura Ophthalmics Announces Enrollment of First Patient in Phase 3 Clinical Trial for AZR-MD-001 in Patients with Meibomian Gland Dysfunction June 4, 2024 TEL AVIV, Israel - June 4, 2024 - Azura Ophthalmics Ltd., a clinical-stage biopharmace

Press Release Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases March 28, 2024 Azura to present 10 abstracts at the American Society of Cataract and Refractive S

Press Release Azura Ophthalmics Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001 in Patients with Contact Lens Discomfort December 18, 2023 Study met its primary endpoint and showed significant and clinically meaningful improvements in

Press Release Azura Ophthalmics to Present New Data on AZR-MD-001 in Meibomian Gland Dysfunction at American Society of Cataract and Refractive Surgery and Association for Research in Vision and Ophthalmology Annual Meetings April 20, 2023 Robust safety a

Press Release Azura Ophthalmics Announces Participation at the 2023 SVB Securities Global Biopharma Conference January 17, 2023 TEL AVIV, Israel & MELBOURNE, Australia, January 17, 2023 - Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company

Press Release Azura Ophthalmics Presents Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction at Ophthalmology Innovation Summit XII December 9, 2022 TEL AVIV, Israel & MELBOURNE, Australia, December 9, 2022 - Azura O

Press Release Azura Ophthalmics Announces Participation at Upcoming Investor Conferences November 21, 2022 TEL AVIV, Israel & MELBOURNE, Australia, November 21, 2022 - Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new the

Press Release Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction November 17, 2022 - AZR-MD-001 0.5% meets co-primary efficacy endpoints, making it the first investigational drug to show

Press Release Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents October 19, 2022 - Supports continued advancement of first-in-class Ophthalmic Keratolytics for ocular surface diseases -TEL AVIV, Israel & MELBO